Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 18 19 20 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
ImCheck Therapeutics–SEVERAL: investment, 201912–202206 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures 2019-12-04
ImCheck Therapeutics–Trophic Communications: public relations, 201912 service existent IR + PR US + EU by Trophic 2019-12-04
ImCheck Therapeutics–Wellington Partners: investment, 201912 financing round Series B totalling €48m incl new + co-investor Wellington Partners 2019-12-04
Indivumed–Biognosys: MS-based proteomics, 201912– collab integration of HRM MS proteomics data into multi-omics IndivuType cancer database 2019-12-02
Innate Pharma–Rentschler: biologics contract manufacturing, –201912 supply service production lacutamab for clinical trials 2019-12-02
MLM Medical Labs–Great Point Partners: investment, 201912 acquistion MLM becomes portfolio company of GPP 2019-12-01
Novartis–Oxford BioMedica: lentiviral vector technology, 201912– supply agreem extension for 5y 2019-12-01
ECBF–EU (govt): investment, 201911–202010 first closing totalling €82m incl cornerstone investor EIB that has committed up to €100m 2019-11-29
ECBF–SEVERAL: investment, 201911–202010 first closing €82m from cornerstone investor EIB + 3 private investors + target size of €250m 2019-11-29
ViGeneron–MC Services: public relations, 201911 service existent media + investor relations by MC Services 2019-11-28
ViGeneron–Sequoia Capital: investment, 201911 financing round Series A incl co-lead investor Sequoia Capital China 2019-11-28
ViGeneron–SEVERAL: investment, 201911 financing round Series A co-led by WuXi AppTec + Sequoia Capital China 2019-11-28
ViGeneron–WuXi PharmaTech: investment, 201911 financing round Series A incl co-lead investor WuXi AppTec 2019-11-28
MaxiVax–EU (govt): grant, 201911 Horizon 2020 EIC Accelerator grant €2.785m 2019-11-26
MaxiVax–SEVERAL: investment, 201911 financing round Series B2 CHF5m from existing + new investors 2019-11-26
Single Use Support–SHS Capital: investment, 201911 investment by SHS Gesellschaft für Beteiligungsmanagement within framework of capital increase 2019-11-26
Ferring–Blackstone: investment, 201911– investment $400m by Blackstone Life Sciences in FerGene to develop + market nadofaragene firadenovec 2019-11-25
Medicines Company–Novartis: investment, 201911–202001 cash tender offer $9.7b at $85/share 2019-11-24
Immunitas Therapeutics–Bayer: investment, 201911 financing round Series A totalling $39m incl co-lead investor Leaps by Bayer 2019-11-21
Immunitas Therapeutics–Evotec: investment, 201911 financing round Series A totalling $39m incl co-investor Evotec 2019-11-21
Immunitas Therapeutics–Merck (DE): investment, 201911 financing round Series A totalling $39m incl co-investor M Ventures 2019-11-21
Immunitas Therapeutics–Novartis: investment, 201911 financing round Series A totalling $39m incl co-lead investor Novartis Venture Fund 2019-11-21
Immunitas Therapeutics–SEVERAL: investment, 201911 financing round Series A $39m co-led by Leaps by Bayer + Novartis Venture Fund 2019-11-21
LabCorp–Qiagen: bioinformatics, 201911– license extension with HGMD in addition ot Qiagen Clinical Insights 2019-11-20
Causaly–SEVERAL: investment, 201911 financing round Series A $5m led by Pentech Ventures + incl EBRD VC + Marathon VC et al. 2019-11-19
CRISPR Therapeutics–SEVERAL: investment, 201911–201912 public offering $315.25m with 4.25m+637.5k common shares at $64.5/share 2019-11-19
Kuros–SEVERAL: investment, 201911–201912 capital increase CHF12.5m with 6.405m new registered shares at CHF1.95/share 2019-11-19
Novartis–Causaly: Natural Language Processing s/w, 201911 collab existent 2019-11-19
Rodin Therapeutics–Alkermes: investment, 201911 acquisition $100m upfront cash + $850m milestones by Alkermes 2019-11-18
Turbine–Atlantic Labs: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Atlantic Labs Manager GmbH 2019-11-13
Turbine–Delin Ventures: investment, 201911 first institutional financing round totalling €3m incl lead investor Delin Ventures 2019-11-13
Turbine–o2h: investment, 201911 first institutional financing round totalling €3m incl new + co-investor o2h Ventures 2019-11-13
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Esther Dyson 2019-11-13
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Vishal Gulati 2019-11-13
Turbine–SEVERAL: investment, 201911 first institutional financing round €3m led by Delin Ventures + incl Atlantic Labs et al. 2019-11-13
Evotec–Merck (DE): CRISPR technology, 201911– license to CRISPR IP portfolio from Merck to Evotec 2019-11-12
Immatics–Genedata: bioinformatics, 201911– license to Genedata Biologics for use with Xceptor TCR discovery + engineering platform 2019-11-12
NEC–Vaximm: cancer vaccines, 201911– collab + option agreem for personalised neoantigen cancer vaccines 2019-11-12
Vaximm–NEC: investment, 201911 equity investment by NEC in connection with collab + option agreem 2019-11-12
Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED 2019-11-11
eGenesis–Bayer: investment, 201911 financing round Series B totalling $100m incl new + co-investor Leaps by Bayer 2019-11-07
eGenesis–Fresenius: investment, 201911 financing round Series B totalling $100m incl lead investor Fresenius Medical Care Ventures 2019-11-07
eGenesis–SEVERAL: investment, 201911 financing round Series B $100m led by Fresenius Medical Care Ventures 2019-11-07
eGenesis–Wellington Partners: investment, 201911 financing round Series B totalling $100m incl new + co-investor Wellington Partners 2019-11-07
Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform 2019-11-07
Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA 2019-11-06
Vifor Pharma–Evotec: drug RnD, 201911– collab establishment 50/50 joint venture for nephrology treatments using NURTuRE biobank + PanHunter s/w 2019-11-06
Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners 2019-11-04
Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners 2019-11-04
Saniva Diagnostics–Xlife Sciences: investment, 201911 investment by Xlife Sciences AG in Saniva Diagnostics GmbH 2019-11-04
Celonis–SEVERAL: investment, 201806 financing round Series B $50m 2019-11-01
Celonis–SEVERAL: investment, 201911 financing round Series C $290m 2019-11-01
Roivant–Sumitomo: investment, 201910 acquisition 10% stake in Roivant by Sumitomo Dainippon Pharma in connection w strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Altavant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Enzyvant Therapeutics by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Myovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Spirovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Roivant–Sumitomo: investment, 201910 acquisition of Roivant shares in Urovant Sciences by Sumitomo Dainippon Pharma as part of strategic alliance 2019-10-31
Sumitomo–Roivant: drug development, 201910– collab strategic alliance $3b upfront incl transfer of 5 vants to Sumitomo Dainippon Pharma 2019-10-31
AstraZeneca–BBG/Braun Group: quetiapine fumarate, 201910– acquisition $178m upfront + up to $61m rights to Seroquel/XR in Europe + RU by Cheplapharm 2019-10-30
Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market 2019-10-28
NikYang Enterprises–Labforward: electonic lab notebook, 201910 collab existent NikYank Enterprises Ltd is Chinese partner of Labforward GmbH 2019-10-24
OpGen–SEVERAL: investment, 201910 underwritten public offering $9.4m 2019-10-23
MCG Motion Capture–Akampion: public relations, 201910 service existent by Akampion 2019-10-22
MCG Motion Capture–Biotech Alliances International: investment banking, 201910– service excl for planned $15m Series A Round of MCG 2019-10-22
MCG Motion Capture–SEVERAL: investment, 201910– PLANNED financing round Series A $15m 2019-10-22
Arcutis Biotherapeutics–HBM: investment, 201910 financing round Series C totalling $94.5m incl new + lead investor HBM Healthcare Investments 2019-10-21
Arcutis Biotherapeutics–SEVERAL: investment, 201910 financing round Series C $94.5m led by HBM Healthcare Investments 2019-10-21
Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal 2019-10-21
Avacta–SEVERAL: investment, 201910– proposed placing + subscription up to £9m with 59.8m nrew ordinary shares at 15p/share 2019-10-18
Plexium–Merck (DE): investment, 201910 financing round Series A totalling $28m incl co-investor M Ventures 2019-10-17
Plexium–SEVERAL: investment, 201910 financing round Series A $28m co-led by DCVC Bio + The Column Group 2019-10-17
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund 2019-10-17
Versameb–SEVERAL: investment, 201910 seed C financing round CHF6.4m bringing total capital raised to CHF11.8m 2019-10-17
Healx–Amadeus Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Amadeus Capital Partners 2019-10-16
Healx–Balderton Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Balderton Capital 2019-10-16
Healx–btov Partners: investment, 201910 financing round Series B totalling $56m incl new + co-investor btov Partners 2019-10-16
Healx–PERSON: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Jonathan Milner 2019-10-16
Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico 2019-10-16
Abalos Therapeutics–Boehringer: investment, 201910 financing round Series A totalling €12m invl co-lead investor BIVF 2019-10-15
Abalos Therapeutics–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling €12m incl co-investor HTGF 2019-10-15
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-investor NRW.BANK 2019-10-15
Abalos Therapeutics–North-Rhine Westphalia (govt): investment, 201910 financing round Series A totalling €12m incl co-lead investor Gründerfonds Ruhr 2019-10-15
Abalos Therapeutics–SEVERAL: investment, 201910 financing round Series A €12m co-led by BIVF + Gründerfonds Ruhr 2019-10-15
Abalos Therapeutics–Trophic Communications: public relations, 201910 service existent by Trophic 2019-10-15
CRISPR Therapeutics–KSQ Therapeutics: CRISPR-based cell therapy, 201910– cross-licensing €na genome editing + CAR-T cell therapy IP 2019-10-15
Biocon–Evotec: biosimilars, 201910– license €na to Biocon Biologics for pre-clinical biosimilar asset of Just-Evotec Biologics 2019-10-10
FloDesign Sonics–Merck (DE): investment, 201910 acquisition €na by Merck 2019-10-10
Celmatix–Evotec: drug discovery services, 201910– collab €na developm pre-clinical programs for reproductive women’s health 2019-10-09
Parexel–Roivant: healthcare informatics, 201910– collab with Datavant multi-year strategic alliance integration of real-world with clinical trial data 2019-10-09
Bayer–RIKEN: drug discovery, 201910– strategic collaboration incl drug target discovery of Bayer Open Innovation Center Japan + RIKEN Innovation 2019-10-08
GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies 2019-10-08
Vivoryon–MC Services: public relations, 201910 service existent by MC Services 2019-10-08
Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG 2019-10-08
Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys 2019-10-08
Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic 2019-10-08
4SC–SEVERAL: investment, 201910–201911 capital increase €22.4m net €22m with 10.65m new shares at €2.1/share with subscription rights 2019-10-07
4SC–Strüngmann Group: investment, 201910 capital increase totalling €22.4m net €22m incl subscription rights for Santo Holding + ATS 2019-10-07
Dalhousie Univ–Thermo Fisher: mass spectrometer, 201910 supply C$1.3m of Orbitrap Fusion MS system to MS + Proteomics Core Faclity 2019-10-07
Illumina–Qiagen: sequencing-based IVD tests, 201910–2034 collab 15y strategic alliance combining sequencing technology + assays + automation + s/w 2019-10-07
next pagenext page 1 2 3 ... 18 19 20 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] No Content Marketing 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x300px

» top